Sleep duration and lipid metabolism in patients with diabetes mellitus: from the POWER2DM study

Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis

Ranges of phenotypic flexibility in healthy subjects

Weight loss predictability by plasma metabolic signatures in adults with obesity and morbid obesity of the DiOGenes study

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes

Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials

Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia

Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations

Effect of moderate alcohol consumption on fetuin-A levels in men and women: Post-hoc analyses of three open-label randomized crossover trials

A physiologically-based kinetic model for the prediction of plasma cholesterol concentrations in the mouse

CETP expression reverses the reconstituted HDL-induced increase in VLDL

Ritonavir protects against the development of atherosclerosis in APOE *3-Leiden mice

The Netherlands twin register biobank: A resource for genetic epidemiological studies

PXR agonism decreases plasma HDL levels in ApoE*3-Leiden.CETP mice

The association of 83 plasma proteins with CHD mortality, BMI, HDL-, and total-cholesterol in men: Applying multivariate statistics to identify proteins with prognostic value and biological relevance

The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo

Plasma apolipoprotein CI protects against mortality from infection in old age

Moderate alcohol consumption and lipoprotein-associated phospholipase A2 activity